2021, Number 2
<< Back Next >>
Med Int Mex 2021; 37 (2)
A patient with severe COVID-19 attended at home and remotely
Ramiro HM
Language: Spanish
References: 6
Page: 306-309
PDF size: 444.95 Kb.
Text Extraction
No abstract.
REFERENCES
Tomazini BM, Mala IS, Cavalcanti AB, Berwanger O, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA 2020; 324 (13): 1307-1316. doi. 10.1001/jama.2020.17021.
RECOVERY Collaborative Group. Hotby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19 - Preliminary report. N Engl J Med 2020. doi. 10.1056/NEJMoa2021436.
Billet HH, Reyes-Gil M, Szymanski J, Ikemura K, et al. Anticoagulation in COVID-19: Effect of enoxaparin, heparin, and apixaban on mortality. Tromb Haemost 2020; 120 (12): 1691-1699. doi. 10.1055/s-0040-1720978.
Atalla HB, Mallah SI, Al-Mahmeed W. Anticoagulation in COVID-19. Eur Heart J Cardiovasc 2020; 6 (4): 260261. doi. 10.1093/ehjcvp/pvaa036.
Rajter JC, Sherman MS, Fatteh N, Vogel F, et al. Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The Ivermectin in COVID Nineteen Study. Chest 2021; 159 (1): 85-92. doi. 10.1016/j.chest.2020.10.009.
Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci 2020; 23: 462-469. doi. 10.18433/jpps31457.
Full text